{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T12:00:37Z","timestamp":1699272037583},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T00:00:00Z","timestamp":1448236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40261-015-0359-6","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T13:13:02Z","timestamp":1448284382000},"page":"147-155","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers"],"prefix":"10.1007","volume":"36","author":[{"given":"Ahmed","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Farid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nouman","family":"Al-Garem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medhat","family":"Al-Ghobashy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,23]]},"reference":[{"key":"359_CR1","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/ndt\/gfh420","volume":"19","author":"S Prakash","year":"2004","unstructured":"Prakash S, et al. Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. Nephrol Dial Transpl. 2004;19:2553\u20138.","journal-title":"Nephrol Dial Transpl."},{"key":"359_CR2","unstructured":"Shire US Inc. ProAmatine (midodrine hydrochloride) tablets: prescribing information. Newport (KY): Shire US Inc.; 2003."},{"key":"359_CR3","first-page":"865","volume":"25","author":"M Akimoto","year":"2004","unstructured":"Akimoto M, et al. The in vitro metabolism of desglymidodrine, an active metabolite of prodrug midodrine by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2004;25:865\u201377.","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"359_CR4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2165\/00002512-199812010-00007","volume":"12","author":"KJ McClellan","year":"1998","unstructured":"McClellan KJ, et al. Midodrine: a review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging. 1998;12:76\u201386.","journal-title":"Drugs Aging."},{"issue":"942","key":"359_CR5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/pgmj.2003.011429","volume":"80","author":"J Naschitz","year":"2004","unstructured":"Naschitz J, et al. Midodrine treatment for chronic fatigue syndrome. Postgrad Med J. 2004;80(942):230\u20132.","journal-title":"Postgrad Med J."},{"key":"359_CR6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1540-8167.1997.tb00607.x","volume":"8","author":"J Sra","year":"1997","unstructured":"Sra J, et al. Efficacy of midodrine in neurocardiogenic syncope refractory to standard therapy. J Cardiovasc Electrophysiol. 1997;8:42\u20136.","journal-title":"J Cardiovasc Electrophysiol."},{"key":"359_CR7","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","volume":"277","author":"PA Low","year":"1997","unstructured":"Low PA, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double blind multicentre study by the Midodrine Study Group. JAMA. 1997;277:1046\u201351.","journal-title":"JAMA."},{"key":"359_CR8","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.hrthm.2008.08.023","volume":"5","author":"V Kuriachan","year":"2008","unstructured":"Kuriachan V, et al. Evidence-based treatment for vasovagal syncope. Heart Rhythm. 2008;5:1609\u201314.","journal-title":"Heart Rhythm."},{"key":"359_CR9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jpeds.2006.07.031","volume":"149","author":"Z Quingou","year":"2006","unstructured":"Quingou Z, et al. The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. J Pediatr. 2006;149:777\u201380.","journal-title":"J Pediatr."},{"key":"359_CR10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.amjmed.2007.02.023","volume":"120","author":"V Gupta","year":"2007","unstructured":"Gupta V, Lipsitz LA. Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med. 2007;120:841\u20137.","journal-title":"Am J Med."},{"key":"359_CR11","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/j.1532-5415.2010.03069.x","volume":"58","author":"D Paling","year":"2010","unstructured":"Paling D, et al. Midodrine hydrochloride is safe and effective in older people with neurocardiogenic syncope. J Am Geriatr Soc. 2010;58:2026\u20137.","journal-title":"J Am Geriatr Soc."},{"key":"359_CR12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14740338.2.1.37","volume":"2","author":"MA Perazella","year":"2003","unstructured":"Perazella MA. Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension. Expert Opin Drug Saf. 2003;2:37\u201347.","journal-title":"Expert Opin Drug Saf."},{"key":"359_CR13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sj.sc.3100959","volume":"38","author":"DB Barber","year":"2000","unstructured":"Barber DB, et al. Midodrine hydrochloride and the treatment of orthostatic hypotension in tetraplegia: two cases and a review of the literature. Spinal Cord. 2000;38:109\u201311.","journal-title":"Spinal Cord."},{"key":"359_CR14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.apmr.2010.06.017","volume":"91","author":"JM Wecht","year":"2010","unstructured":"Wecht JM, et al. Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia. Arch Phys Med Rehab. 2010;91:1429\u201335.","journal-title":"Arch Phys Med Rehab."},{"key":"359_CR15","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047\u201360.","journal-title":"Circulation."},{"key":"359_CR16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/j.1552-4604.1994.tb04988.x","volume":"34","author":"SE Piwinski","year":"1994","unstructured":"Piwinski SE, et al. A comparison of post space flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha-agonist for these conditions. J Clin Pharmacol. 1994;34:466\u201371.","journal-title":"J Clin Pharmacol."},{"key":"359_CR17","unstructured":"Such J, Runyon BA. Treatment of diuretic-resistant ascites in patients with cirrhosis. In: Travis (ed). Up to date. http:\/\/www.uptodate.com\/contents\/ascites-in-adults-with-cirrhosis-diuretic-resistant-ascites+&cd=2&hl=en&ct=clnk&gl=eg . Accessed 19 Dec 2014."},{"key":"359_CR18","first-page":"1915","volume":"61","author":"A Ali","year":"2014","unstructured":"Ali A, et al. Clinical study on the therapeutic role of midodrine in non-azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial. Hepatogastroenterology. 2014;61:1915\u201324.","journal-title":"Hepatogastroenterology"},{"key":"359_CR19","doi-asserted-by":"crossref","unstructured":"Carlson RV et al. The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharmacol. 2004;57(6):695\u2013713.","DOI":"10.1111\/j.1365-2125.2004.02103.x"},{"key":"359_CR20","first-page":"119","volume":"12","author":"HF Grobecker","year":"1993","unstructured":"Grobecker HF, Kees F. Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. Int Angiol. 1993;12:119\u201324.","journal-title":"Int Angiol."},{"issue":"991","key":"359_CR21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jchromb.2015.03.032","volume":"1","author":"A Ali","year":"2015","unstructured":"Ali A, et al. Development and validation of LC\u2013MS\/MS assay for the determination of the prodrug midodrine and its active metabolite desglymidodrine in plasma of ascitic patients: application to individualized therapy and comparative pharmacokinetics. J Chromatogr B. 2015;1(991):34\u201340.","journal-title":"J Chromatogr B"},{"key":"359_CR22","unstructured":"DailyMed. http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=31527 . Accessed 11 June 2014."},{"key":"359_CR23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1345\/aph.1L373","volume":"43","author":"R Karwa","year":"2009","unstructured":"Karwa R, Woodis B. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother. 2009;43:692\u20139.","journal-title":"Ann Pharmacother."},{"key":"359_CR24","first-page":"120","volume":"21","author":"J George","year":"1995","unstructured":"George J, et al. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology. 1995;21:120\u20138.","journal-title":"Hepatology."},{"issue":"7","key":"359_CR25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","volume":"31","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31(7):815\u201332.","journal-title":"Drug Metab Dispos."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0359-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0359-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0359-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:56Z","timestamp":1559503736000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0359-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,23]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0359-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,23]]}}}